Real-world analysis of factors influencing turnaround time (TAT) for tissue comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC).

A Adam Fox (Medical University of South Carolina, Charleston, SC) R Rachel B. Keller-Evans (Foundation Medicine, Inc., Boston, MA) G Gerald Li (Foundation Medicine, Inc., Boston, MA) R Richard Sheng Poe Huang (Foundation Medicine, Inc., Boston, MA) G Gerard A. Silvestri (Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston)

Abstract

11161 Background: CGP is an integral part of the standard of care for many solid tumor malignancies, and especially for NSCLC, as testing informs first-line treatment selection at most stages. CGP TAT is understudied but has implications for appropriate treatment delivery and patient outcomes. Methods: In this retrospective cohort analysis, TAT was calculated for U.S. tissue CGP testing orders received between January 2021 and September 2023 at a centralized commercial molecular laboratory (Foundation Medicine, Inc., Cambridge, MA, USA). Ordering TAT (specimen collection to CGP ordering), Specimen TAT (CGP ordering to specimen receipt at testing lab), Molecular TAT (specimen receipt to results reporting), and Overall TAT (specimen collection to results reporting) were calculated. Cases were excluded if CGP was ordered >6 months after specimen collection or if missing TAT data. Descriptive statistics and linear regression modeling for association of TAT with available clinical and molecular factors were performed. Results: A total of 40,728 NSCLC biopsies from 547 institutions were included in the analysis. The median Overall TAT for all samples was 29.8 days (IQR: 21.7, 44.6). Median times for Ordering TAT, Specimen TAT, and Molecular TAT were 14.8 days (IQR: 8.4, 27.8), 3.2 days (IQR: 1.3, 6.2), and 9.0 days (IQR: 7.7, 11.0), respectively. Aggregating and calculating TAT at the institution level, the median Overall TAT was 40.6 days (IQR: 38.5, 43.8) versus 21.9 days (IQR: 20.7, 23.7) among the slowest and fastest Overall TAT quintiles, respectively; Ordering TAT [median 15.1, IQR: 11.6, 18.9] and Specimen TAT [median 3.9, IQR: 1.9, 5.1] contributed to this variability, while Molecular TAT [median 9.0, IQR: 8.6, 9.3] remained consistent. Higher institutional order volume was the strongest predictor of shorter Overall TAT (-6.59 days [95% CI: -7.46, -5.71] for institutions with [100-200) vs <20 orders, P < .001), largely driven by variability in Ordering TAT (-4.13 days [95% CI: -4.95, -3.31] for institutions with [100-200) vs <20 orders, P < .001) and Specimen TAT (-2.25 days [95% CI: -2.47, -2.04] for institutions with [100-200) vs <20 orders, P < .001). Conclusions: This study demonstrates that NSCLC CGP TAT is highly variable and is influenced by institutional factors, particularly higher institutional ordering volume. For patients with an established diagnosis, the time between specimen collection/diagnosis and CGP ordering likely represents the longest and most modifiable component of Overall TAT. This study raises the hypothesis that adoption of coordinated interventions, such as reflex testing, could reduce Ordering TAT, and thus Overall TAT, for many patients.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 11161-11161
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (5)

A

Adam Fox

Medical University of South Carolina, Charleston, SC

R

Rachel B. Keller-Evans

Foundation Medicine, Inc., Boston, MA

G

Gerald Li

Foundation Medicine, Inc., Boston, MA

R

Richard Sheng Poe Huang

Foundation Medicine, Inc., Boston, MA

G

Gerard A. Silvestri

Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston